ドラッグデリバリーの世界市場：薬剤用量、薬価、売上、臨床試験動向（2030年）

ドラッグデリバリーの世界市場：薬剤用量、薬価、売上、臨床試験動向（2030年）レポート所見とハイライト：

• 調査手法
• 世界市場と地域市場の概要
• 世界市場規模（単位：10億米ドル）：2022年～2030年
• 世界市場の機会：900億米ドル以上
• 臨床試験中の放出制御薬に関する洞察：190品目以上
• 企業別、適応症別、相別の放出制御薬の世界臨床パイプライン
• 承認・上市された放出制御薬に関する洞察：180品目以上
• 放出制御薬の用量、価格、販売に関する洞察
• 競合情勢

ドラッグデリバリー制御システムの必要性と当レポートの意義

ヘルスケア従事者と患者の両方が、より改善された、より便利で安全な治療レジメンを求めているため、ドラッグデリバリー制御システムの需要が高まっています。糖尿病、心血管疾患、神経疾患などの慢性疾患は長期的な治療が必要であり、反復投与や薬剤吸収の変動など、従来の投与に関連する制限は治療効果をしばしば損ないます。ドラッグデリバリー制御システムは、長期間にわたって薬剤のレベルを一定に保ち、投与回数を最小限に抑え、治療効果を向上させることで、これらの問題を解決します。ドラッグデリバリー制御システムはまた、副作用の軽減、患者のコンプライアンス、薬剤の薬剤動態の最適化にも役立ちます。

当レポートでは、革新技術、臨床動向、主要市場参入企業を取り上げ、ドラッグデリバリー制御技術の変化する情勢を詳細に考察しています。ドラッグデリバリーの改善に対する需要が高まる中、本分析はこの成長市場における将来の成長と機会を見通すものです。最新の技術開発や新たな動向のほか、60以上の医薬品の詳細な価格データや特定の製品の販売実績データも掲載しています。この戦略的提言と市場データの融合は、市場参入企業が医薬品開発、デリバリー、商品化において十分な情報に基づいた意思決定を行うための指針となるものです。

レポートに含まれる臨床試験に関する洞察

臨床試験は、放出制御型ドラッグデリバリーシステムの有効性と安全性を検証する上で極めて重要です。当レポートでは、いくつかの主な臨床試験に関する詳細な洞察を掲載し、この分野の開発を展望しています。このセクションで提供される情報は、試験の段階、スポンサー、地理的分布、技術提供者、共同研究者、ライセンシングホルダーで構成されています。試験は、疼痛管理や腫瘍学から神経疾患や代謝性疾患まで、さまざまな治療カテゴリーをカバーしています。

ドラッグデリバリー制御システムの研究開発に積極的な主要企業

現在、多くの大手製薬企業やバイオテクノロジー企業がドラッグデリバリー制御システムの開発に携わっています。これらの企業は研究開発活動のリーダーであり、より効率的で患者に優しい医薬品を開発するために先進技術を採用しています。当レポートでは、AbbVie、AstraZeneca、Merckなど、慢性疾患だけでなく、がん、神経疾患、代謝性疾患などの治療を強化するための新しいドラッグデリバリープラットフォームを探している著名な企業を特定しています。

大手製薬会社とともに、小規模な新興企業も新しい放出制御システムの開発で主導権を握っています。SpyGlass PharmaやGlaukos Corporationのような企業は、眼科領域における放出制御プラットフォームの限界に課題しており、一方、Boehringer IngelheimとRe-Vana Therapeuticsのようなパートナーシップは、網膜疾患のための生分解性インプラントを開発しています。また、こうした提携が新世代のドラッグデリバリーシステムの商業化にどのように拍車をかけているかについても解説しています。

ドラッグデリバリー制御システム分野の今後の方向性を示すレポート

ドラッグデリバリー制御システムの将来は、大きな成長と開発が期待されます。同レポートによると、バイオテクノロジーとデジタルヘルス技術の発展により、より個別化された標的薬剤送達メカニズムの使用が重視されるようになります。精密医療の出現は、各患者の要求に応えるカスタマイズされたドラッグデリバリーシステムの創出を推進し、治療効果と患者のコンプライアンスをさらに高めると思われます。

さらに、埋込み型システムや経皮パッチを含む非侵襲的ドラッグデリバリー技術は、利便性が高く患者への不快感も少ないため、より広範に使用されることが我々の調査で予想されています。神経変性疾患、個別化腫瘍学、希少疾患への応用の拡大も、市場を前進させると思われます。

研究開発への投資が継続され、革新的なドラッグデリバリー技術に対する規制当局の支援がさらに強化されるにつれて、ドラッグデリバリー制御システム市場の成長は持続し、このような高度な治療法を開発する企業には大きな機会がもたらされるとみられています。

目次

第1章 制御型ドラッグデリバリーのイントロダクション

• ファンデーションとテクノロジー
• システム、ルート、技術別分類
• 作用機序

第2章 制御型ドラッグデリバリーのための材料ベースのアプローチ

• ポリマー
• クロノファーマシューティクス
• ナノ粒子送達システム

第3章 世界の徐放性ドラッグデリバリー市場の動向

• 現在の市場シナリオ
• 将来の市場見通し

第4章 制御ドラッグデリバリーの研究と臨床動向、適応症別

• 神経疾患
• 心血管疾患
• 糖尿病
• がん
• 微生物感染症

第5章 世界の徐放性医薬品市場の動向、地域別

• 米国
• 欧州
• 日本
• 中国
• カナダ
• 韓国

第6章 企業別、適応症別、相別の世界徐放性医薬品の臨床パイプライン

• 研究
• 前臨床
• 第I相
• 第I/II相
• 第II相
• 第II/III相
• 第III相
• 事前登録
• 登録済み

第7章 市販されている徐放性医薬品の企業別、国別、適応症別の臨床的洞察

第8章 アルツハイマー病の徐放性薬剤- 価格と用量の考察

• ナムザリック（徐放性）
• ナメンダXR（徐放性）
• ラザダインER（徐放性）

第9章 パーキンソン病の徐放性薬剤- 価格と用量の考察

• ゴコブリ（徐放性）
• オスモレックスER（徐放性）
• ミラペックスER（徐放性）

第10章 統合失調症の徐放性薬剤- 価格と用量の考察

• インヴェガ（徐放性）
• Invegaフランチャイズ/Invega Hafyera（徐放性）
• セロクエルXR（徐放性）
• エビリファイフランチャイズ（徐放性）
• アリスタダ/アリスタダ・イニティオ（徐放性）
• リキンド（徐放性）
• リスパダール・コンスタ（徐放性）
• ウゼディ（徐放性）

第11章 慢性疼痛および術後疼痛に対する徐放性薬剤- 価格と用量の考察

• Hysingla ER（徐放性）
• ヌシンタER（徐放性）
• カディアン（徐放性）
• Xtampza ER（徐放性）
• MSコンチン（徐放性）
• エンベダ（徐放性）
• ポジミール（徐放性）
• ジンレリーフ（徐放性）
• ConZip（徐放性）
• ジェネリックヒドロモルフォン（徐放性）

第12章 多発性硬化症に対する徐放性薬剤- 価格と用量の考察

• アンピラ/ファンピラ（徐放性）
• テクフィデラ（遅延放出性）
• ヴメリティ（遅延放出性）
• レイオス（遅延放出性）
• バフィエルタム（遅延放出性）

第13章 2型糖尿病に対する徐放性薬剤- 価格と用量の考察

• グルメツァ（徐放性）
• グルコトロールXL（徐放性）
• グルコファージXR（徐放性）
• トリジャルディXR（徐放性）
• シンジャルディXR（徐放性）

第14章 心血管疾患に対する徐放性薬剤- 価格と用量の考察

• プロカルディアXL（徐放性）
• トップロールXL（徐放性）
• ヴェレランPM（徐放性）
• カルディゼムLA（徐放性）
• カランSR（徐放性）
• アルトプレブ（徐放性）
• カルデュラXL（徐放性）

第15章 HIVに対する徐放性薬剤- 価格と用量の考察

• アプレチュード（徐放性）
• カベヌーバ（徐放性）
• ルコビア（徐放性）

第16章 注意欠陥・多動性障害（ADHD）に対する徐放性薬剤- 価格と用量の考察

• ケルブリー（徐放性）
• ジョルネPM（徐放性）
• コテンプラXR-ODT（徐放性）
• アゼニスXR-ODT（徐放性）
• インチュニブ（徐放性）
• フォカリンXR（徐放性）

第17章 炎症性疾患および自己免疫疾患に対する徐放性薬剤- 価格と用量の考察

• リンヴォック（徐放性）
• オルティコス（徐放性）
• ゼルヤンツXR（徐放性）
• メスチノンタイムスパン（徐放性）
• シマックスデュオタブ（徐放性）

第18章 細菌感染症に対する徐放性薬剤- 価格と用量の考察

• アエムコロ（遅延放出性）
• タリシア（遅延放出性）

第19章 オピオイド使用障害に対する徐放性薬剤- 価格と用量の考察

• サブロケード（徐放性）
• ブリクサディ（徐放性）

第20章 臓器移植拒絶反応抑制のための徐放性薬剤- 価格と用量の考察

• アスタグラフXL（徐放性）
• エンバルサスXR（徐放性）

第21章 片頭痛と発作に対する徐放性薬剤- 価格と用量の考察

• トロケンディXR（徐放性）
• オックステラーXR（徐放性）
• ケプラXR（徐放性）
• ロウィープラXR（徐放性）
• デパコス、デパコスER、デパコススリンクル

第22章 精神疾患および睡眠障害に対する徐放性薬剤- 価格と用量の考察

• エフェクサーXR（徐放性）
• ザナックスXR（徐放性）
• アンビエンCR（徐放性）

第23章 代謝・電解質異常に対する徐放性薬剤- 価格と用量の考察

• クロールコン8、クロールコン10、クロールコンM10、クロールコンM15、クロールコンM20

第24章 世界なドラッグデリバリーシステム市場力学

• 市場促進要因と機会
• 市場の課題と抑制要因

第25章 競合情勢

• AbbVie
• Antlia Bioscience
• Arbor Pharmaceuticals (Azurity Pharmaceuticals)
• AstraZeneca
• Bausch Health Companies
• Biodexa Pharmaceuticals
• Boehringer Ingelheim
• Camurus
• DURECT Corporation
• Emplicure
• HLK Pharmacin
• Jemincare
• Johnson & Johnson
• Luye Pharma Group
• Lyndra
• Mallinckrodt plc
• MedinCell S.A.
• Merck
• Otsuka Pharmaceutical
• Pacira BioSciences
• Pfizer
• Purdue Pharma
• Roche
• Sanofi
• Serina Therapeutics
• Sun Pharmaceutical Industries
• Supernus Pharmaceuticals
• Takeda
• Tris Pharma
• ViiV Healthcare

List of Figures

• Figure 1-1: Conventional Drug Delivery Systems - Limitations
• Figure 1-2: Novel Drug Delivery Platform Diversification
• Figure 1-3: Evolution Of Drug Delivery Technology: 1st to 3rd Generation
• Figure 1-4: Challenges Addressed By Third Generation Drug Delivery
• Figure 1-5: Targeted vs. Non-Targeted Drug Delivery
• Figure 1-6: Zero-Order Controlled Drug Release
• Figure 1-7: Plasma Concentration-Time Profile: Conventional vs. Controlled Release
• Figure 1-8: Comparison Of Modified Drug Release Systems
• Figure 1-9: Pulsatile Drug Release Mechanism In Pulsincap
• Figure 1-10: Classification By Technical Complexity
• Figure 1-11: Structural Differences Among Drug Delivery Systems
• Figure 1-12: Classification By Route of Administration
• Figure 1-13: Types Of Diffusion-Controlled Mechanisms
• Figure 1-14: Encapsulation Dissolution-Controlled Mechanism
• Figure 1-15: Osmotic Controlled Drug Release
• Figure 1-16: Erosion Mechanisms In Matrix Systems
• Figure 2-1: Polymeric Controlled Drug Delivery Devices - Categories
• Figure 2-2: Nanostructures For Nanoparticulate Delivery Systems
• Figure 3-1: Global - Controlled Release Drug Delivery Market Size (US$ Billion), 2022 - 2025
• Figure 3-2: Global - Controlled Release Drug Delivery Market Forecast (US$ Billion), 2026 - 2030
• Figure 4-1: Major Non-Invasive Routes For Insulin Delivery
• Figure 4-2: Controlled Drug Delivery Strategies In Cancer Therapy
• Figure 6-1: Global - Controlled Release Drug Clinical Pipeline By Phase (Number), 2025 Till 2030
• Figure 8-1: Namzaric - Price Per Unit & Supply (US$), August'2025
• Figure 8-2: Generic Donepezil/Memantine - Price Per Unit & Supply (US$), August'2025
• Figure 8-3: Namenda XR - Price Per Unit & Supply Of 7mg & 21mg Extended Release Capsules (US$), August'2025
• Figure 8-4: Namenda XR - Price Per Unit & Supply Of 14mg & 28mg Extended Release Capsules (US$), August'2025
• Figure 8-5: Namenda XR - Price Per Unit & Supply Of Extended Release Oral Kit (US$), August'2025
• Figure 8-6: Generic Memantine - Price Per Unit & Supply Of 7mg & 21mg Extended Release Capsules (US$), August'2025
• Figure 8-7: Generic Memantine - Price Per Unit & Supply Of 14mg Extended Release Capsules (US$), August'2025
• Figure 8-8: Generic Memantine - Price Per Unit & Supply Of 28mg Extended Release Capsules (US$), August'2025
• Figure 8-9: Razadyne ER - Price Per Unit & Supply (US$), August'2025
• Figure 8-10: Generic Galantamine - Price Per Unit & Supply (US$), August'2025
• Figure 9-1: Gocovri - Price Per Unit & Supply (US$), August'2025
• Figure 9-2: Global - Gocovri Annual Sales (US$ Million), 2021-2025
• Figure 9-3: Global - Gocovri Quarterly Sales (US$ Million), Q1 & Q2'2025
• Figure 9-4: Global - Gocovri Quarterly Sales (US$ Million), Q1-Q4'2024
• Figure 9-5: Osmolex ER - Price Per Unit & Supply Of 322 mg Extended Release Tablet (US$), August'2025
• Figure 9-6: Osmolex ER - Price Per Unit & Supply Of 129 mg Extended Release Tablet (US$), August'2025
• Figure 9-7: Osmolex ER - Price Per Unit & Supply Of 193 mg Extended Release Tablet (US$), August'2025
• Figure 9-8: Osmolex ER - Price Per Unit & Supply Of 258 mg Extended Release Tablet (US$), August'2025
• Figure 9-9: Mirapex ER - Available Dosage Strengths (mg)
• Figure 9-10: Mirapex ER - Price Per Unit & Supply Of 0.375 mg & 0.75 mg Extended Release Tablets (US$), August'2025
• Figure 9-11: Mirapex ER - Price Per Unit & Supply Of 1.5 mg Extended Release Tablet (US$), August'2025
• Figure 9-12: Mirapex ER - Price Per Unit & Supply Of 2.25 mg, 3 mg, 3.75 mg & 4.5 mg Extended Release Tablets (US$), August'2025
• Figure 9-13: Generic Pramipexole - Price Per Unit & Supply Of 0.375 mg & 0.75 mg (US$), August'2025
• Figure 9-14: Generic Pramipexole - Price Per Unit & Supply Of 1.5 mg, 2.25 mg, 3 mg, & 4.5 mg (US$), August'2025
• Figure 9-15: Generic Pramipexole - Price Per Unit & Supply Of 3.75 mg (US$), August'2025
• Figure 10-1: Invega - Available Dosage Strengths (mg)
• Figure 10-2: Invega - Price Per Unit & Supply (US$), August'2025
• Figure 10-3: Invega Sustenna - Price Per Unit & Supply (US$), August'2025
• Figure 10-4: Invega Trinza - Price Per Unit & Supply (US$), August'2025
• Figure 10-5: Invega Hafyera - Price Per Unit & Supply (US$), August'2025
• Figure 10-6: Global - Invega Franchise Annual Sales (US$ Million), 2020-2025
• Figure 10-7: Global - Invega Franchise Quarterly Sales (US$ Million), Q1 & Q2'2025
• Figure 10-8: Global - Invega Franchise Quarterly Sales (US$ Million), Q1-Q4'2024
• Figure 10-9: US - Invega Franchise Annual Sales (US$ Million), 2020-2025
• Figure 10-10: US - Invega Franchise Quarterly Sales (US$ Million), Q1 & Q2'2025
• Figure 10-11: US - Invega Franchise Quarterly Sales (US$ Million), Q1-Q4'2024
• Figure 10-12: ROW - Invega Franchise Annual Sales (US$ Million), 2020-2025
• Figure 10-13: ROW - Invega Franchise Quarterly Sales (US$ Million), Q1 & Q2'2025
• Figure 10-14: ROW - Invega Franchise Quarterly Sales (US$ Million), Q1-Q4'2024
• Figure 10-15: Seroquel XR - Available Dosage Strengths (mg)
• Figure 10-16: Seroquel XR - Price Per Unit & Supply (US$), August'2025
• Figure 10-17: Generic Quetiapine - Price Per Unit & Supply Of 60 Tablets (US$), August'2025
• Figure 10-18: Generic Quetiapine - Price Per Unit & Supply Of 100 Tablets (US$), August'2025
• Figure 10-19: Global - Seroquel XR Total Annual Sales (US$ Million), 2020-2021
• Figure 10-20: Abilify Maintena - Available Dosage Strengths (mg)
• Figure 10-21: Abilify Maintena - Price Per Supply of Vial & Prefilled Syringe (US$), August'2025
• Figure 10-22: Abilify Asimtufii - Price Per Unit & Supply (US$), August'2025
• Figure 10-23: Global - Abilify Franchise Annual Sales (US$ Million), 2020-2025
• Figure 10-24: Global - Abilify Franchise Quarterly Sales (US$ Million), Q1 & Q2'2025
• Figure 10-25: Global - Abilify Franchise Quarterly Sales (US$ Million), Q1-Q4'2024
• Figure 10-26: Aristada - Available Dosage Strengths (mg)
• Figure 10-27: Aristada - Price Per Unit & Supply (US$), August'2025
• Figure 10-28: Aristada Initio - Price Per Unit & Supply (US$), August'2025
• Figure 10-29: Global - Aristada Franchise Annual Sales (US$ Million), 2020-2025
• Figure 10-30: Global - Aristada Franchise Quarterly Sales (US$ Million), Q1 & Q2'2025
• Figure 10-31: Global - Aristada Franchise Quarterly Sales (US$ Million), Q1-Q4'2024
• Figure 10-32: Rykindo - Available Dosage Strengths (mg)
• Figure 10-33: Rykindo - Price Per Supply (US$), August'2025
• Figure 10-34: Generic Risperidone - Price Per Supply (US$), August'2025
• Figure 10-35: Risperdal Consta - Price Per Supply (US$), August'2025
• Figure 10-36: Global - Risperdal Consta Annual Sales (US$ Million), 2020-2021
• Figure 10-37: Uzedy - Price Per Unit & Supply (US$), August'2025
• Figure 11-1: Hysingla ER - Available Dosage Strengths (mg)
• Figure 11-2: Hysingla ER - Price Per Unit & Supply (US$), August'2025
• Figure 11-3: Generic Hydrocodone - Price Per Unit & Supply (US$), August'2025
• Figure 11-4: Nucynta ER - Available Dosage Strengths (mg)
• Figure 11-5: Nucynta ER - Price Per Unit & Supply (US$), August'2025
• Figure 11-6: Global - Nucynta ER Annual Sales (US$ Million), 2020-2025
• Figure 11-7: Global - Nucynta ER Quarterly Sales (US$ Million), Q1 & Q2'2025
• Figure 11-8: Global - Nucynta ER Quarterly Sales (US$ Million), Q1-Q4'2024
• Figure 11-9: Kadian - Available Dosage Strengths (mg)
• Figure 11-10: Kadian - Price Per Unit & Supply Of Strength 10 mg/12 hr (US$), August'2025
• Figure 11-11: Kadian - Price Per Unit & Supply Of Strength 10 mg/12 to 24 hr & 10 mg/24 hr (US$), August'2025
• Figure 11-12: Kadian - Price Per Unit & Supply Of Strength 20 mg/12 hr (US$), August'2025
• Figure 11-13: Kadian - Price Per Unit & Supply Of Strength 20 mg/12 to 24 hr & 20 mg/24 hr (US$), August'2025
• Figure 11-14: Kadian - Price Per Unit & Supply Of Strength 30 mg/12 hr (US$), August'2025
• Figure 11-15: Kadian - Price Per Unit & Supply Of Strength 30 mg/12 to 24 hr & 30 mg/24 hr (US$), August'2025
• Figure 11-16: Kadian - Price Per Unit & Supply Of Strength 40 mg/12 to 24 hr & 40 mg/24 hr (US$), August'2025
• Figure 11-17: Kadian - Price Per Unit & Supply Of Strength 50 mg/12 hr (US$), August'2025
• Figure 11-18: Kadian - Price Per Unit & Supply Of Strength 50 mg/12 to 24 hr & 50 mg/24 hr (US$), August'2025
• Figure 11-19: Kadian - Price Per Unit & Supply Of Strength 60 mg/12 hr (US$), August'2025
• Figure 11-20: Kadian - Price Per Unit & Supply Of Strength 60 mg/12 to 24 hr (US$), August'2025
• Figure 11-21: Kadian - Price Per Unit & Supply Of Strength 60 mg/24 hr (US$), August'2025
• Figure 11-22: Kadian - Price Per Unit & Supply Of Strength 70 mg/12 to 24 hr (US$), August'2025
• Figure 11-23: Kadian - Price Per Unit & Supply Of Strength 80 mg/12 hr, 80 mg/12 to 24 hr & 80 mg/24 hr (US$), August'2025
• Figure 11-24: Kadian - Price Per Unit & Supply Of Strength 100 mg/12 hr, 100 mg/12 to 24 hr & 100 mg/24 hr (US$), August'2025
• Figure 11-25: Kadian - Price Per Unit & Supply Of Strength 130 mg/12 to 24 hr & 150 mg/12 to 24 hr (US$), August'2025
• Figure 11-26: Kadian - Price Per Unit & Supply Of Strength 200 mg/12 to 24 hr & 200 mg/24 hr (US$), August'2025
• Figure 11-27: Xtampza ER - Available Dosage Strengths (mg)
• Figure 11-28: Xtampza ER - Price Per Unit & Supply (US$), August'2025
• Figure 11-29: Global - Xtampza ER Annual Sales (US$ Million), 2020-2025
• Figure 11-30: Global - Xtampza ER Quarterly Sales (US$ Million), Q1 & Q2'2025
• Figure 11-31: Global - Xtampza ER Quarterly Sales (US$ Million), Q1-Q4'2024
• Figure 11-32: MS Contin - Available Dosage Strengths (mg)
• Figure 11-33: MS Contin - Price Per Unit & Supply (US$), August'2025
• Figure 11-34: Embeda - Price Per Unit & Supply (US$), August'2025
• Figure 11-35: Zynrelef - Price Per Unit & Supply (US$), August'2025
• Figure 11-36: Global - Zynrelef Annual Sales (US$ Million), 2021-2025
• Figure 11-37: Global - Zynrelef Quarterly Sales (US$ Million), H1'2025
• Figure 11-38: Global - Zynrelef Quarterly Sales (US$ Million), 2024
• Figure 11-39: ConZip - Available Dosage Strengths (mg)
• Figure 11-40: ConZip - Price Per Unit & Supply (US$), August'2025
• Figure 11-41: Generic Hydromorphone - Available Dosage Strengths (mg)
• Figure 11-42: Generic Hydromorphone - Price Per Unit & Supply (US$), August'2025
• Figure 12-1: Ampyra - Price Per Unit & Supply (US$), August'2025
• Figure 12-2: Generic Dalfampridine - Price Per Unit & Supply (US$), August'2025
• Figure 12-3: ROW - Fampyra Annual Sales (US$ Million), 2020-2025
• Figure 12-4: ROW - Fampyra Quarterly Sales (US$ Million), Q1-Q4'2024
• Figure 12-5: Tecfidera - Available Dosage Strengths (mg)
• Figure 12-6: Tecfidera - Price Per Unit & Supply (US$), August'2025
• Figure 12-7: Generic Dimethyl Fumarate - Price Per Unit & Supply (US$), August'2025
• Figure 12-8: Global - Tecdifera Annual Sales (US$ Million), 2020-2025
• Figure 12-9: Global - Tecdifera Quarterly Sales (US$ Million), Q1 & Q2'2025
• Figure 12-10: Global - Tecdifera Quarterly Sales (US$ Million), Q1-Q4'2024
• Figure 12-11: US - Tecdifera Annual Sales (US$ Million), 2020-2025
• Figure 12-12: US - Tecdifera Quarterly Sales (US$ Million), Q1 & Q2'2025
• Figure 12-13: US - Tecdifera Quarterly Sales (US$ Million), Q1-Q4'2024
• Figure 12-14: ROW - Tecdifera Annual Sales (US$ Million), 2020-2025
• Figure 12-15: ROW - Tecdifera Quarterly Sales (US$ Million), Q1 & Q2'2025
• Figure 12-16: ROW - Tecdifera Quarterly Sales (US$ Million), Q1-Q4'2024
• Figure 12-17: Vumerity - Price Per Unit & Supply (US$), August'2025
• Figure 12-18: Global - Vumerity Annual Sales (US$ Million), 2020-2025
• Figure 12-19: Global - Vumerity Quarterly Sales (US$ Million), Q1 & Q2'2025
• Figure 12-20: Global - Vumerity Quarterly Sales (US$ Million), Q1-Q4'2024
• Figure 12-21: US - Vumerity Annual Sales (US$ Million), 2020-2025
• Figure 12-22: US - Vumerity Quarterly Sales (US$ Million), Q1 & Q2'2025
• Figure 12-23: US - Vumerity Quarterly Sales (US$ Million), Q1-Q4'2024
• Figure 12-24: ROW - Vumerity Annual Sales (US$ Million), 2020-2025
• Figure 12-25: ROW - Vumerity Quarterly Sales (US$ Million), Q1 & Q2'2025
• Figure 12-26: ROW - Vumerity Quarterly Sales (US$ Million), Q1-Q4'2024
• Figure 12-27: Rayos - Available Dosage Strengths (mg)
• Figure 12-28: Rayos - Price Per Unit & Supply (US$), August'2025
• Figure 12-29: US - Rayos Annual Sales (US$ Million), 2020-2023
• Figure 12-30: Global - Rayos Quarterly Sales (US$ Million), H1'2023
• Figure 12-31: Bafiertam - Price Per Unit & Supply (US$), August'2025
• Figure 13-1: Glumetza - Available Dosage Strengths (mg)
• Figure 13-2: Glumetza - Price Per Unit & Supply (US$), August'2025
• Figure 13-3: Generic Metformin - Price Per Unit & Supply Of 500mg (US$), August'2025
• Figure 13-4: Generic Metformin - Price Per Unit & Supply Of 1000mg (US$), August'2025
• Figure 13-5: Glucotrol XL - Available Dosage Strengths (mg)
• Figure 13-6: Glucotrol XL - Price Per Unit & Supply Of Strength 5 mg (US$), August'2025
• Figure 13-7: Glucotrol XL - Price Per Unit & Supply Of Strength 10 mg (US$), August'2025
• Figure 13-8: Generic Glipizide - Price Per Unit & Supply Of Strength 5 mg (US$), August'2025
• Figure 13-9: Generic Glipizide - Price Per Unit & Supply Of Strength 10 mg (US$), August'2025
• Figure 13-10: Glucophage XR - Available Dosage Strengths (mg)
• Figure 13-11: Glucophage XR - Price Per Unit & Supply Of Strength 10 mg (US$), August'2025
• Figure 13-12: Glucophage XR - Price Per Unit & Supply Of Strength 750 mg (US$), August'2025
• Figure 13-13: Trijardy XR - Price Per Unit & Supply Of Strengths 10 mg-5 mg-1000 mg & 25 mg-5 mg-1000 mg (US$), August'2025
• Figure 13-14: Trijardy XR - Price Per Unit & Supply Of Strengths 10 mg-5 mg-1000 mg & 25 mg-5 mg-1000 mg (US$), August'2025
• Figure 13-15: Synjardy XR - Price Per Unit & Supply Of 10 mg-1000 mg & 25 mg-1000 mg (US$), August'2025
• Figure 13-16: Synjardy XR - Price Per Unit & Supply Of 5 mg-1000 mg & 12.5 mg-1000 mg (US$), August'2025
• Figure 14-1: Procardia XL - Available Dosage Strengths (mg)
• Figure 14-2: Procardia XL - Price Per Unit & Supply Of 100 Tablets (US$), August'2025
• Figure 14-3: Procardia XL - Price Per Unit & Supply Of 300 Tablets (US$), August'2025
• Figure 14-4: Toprol XL - Available Dosage Strengths
• Figure 14-5: Toprol XL - Price Per Unit & Supply Of Strengths 25 mg, 50 mg & 200 mg (US$), August'2025
• Figure 14-6: Toprol XL - Price Per Unit & Supply Of Strengths 100 mg (US$), August'2025
• Figure 14-7: Global - Toprol XL Annual Sales (US$ Million), 2020-2024
• Figure 14-8: Global - Toprol XL Quarterly Sales (US$ Million), Q1-Q4'2024
• Figure 14-9: US - Toprol XL Annual Sales (US$ Million), 2020-2024
• Figure 14-10: EU - Toprol XL Quarterly Sales (US$ Million), Q1-Q4'2024
• Figure 14-11: EU - Toprol XL Annual Sales (US$ Million), 2020-2024
• Figure 14-12: EU - Toprol XL Quarterly Sales (US$ Million), Q1-Q4'2024
• Figure 14-13: ROW - Toprol XL Annual Sales (US$ Million), 2020-2024
• Figure 14-14: ROW - Toprol XL Quarterly Sales (US$ Million), Q1-Q4'2024
• Figure 14-15: Verelan PM - Available Dosage Strengths (mg)
• Figure 14-16: Verelan PM - Price Per Unit & Supply (US$), August'2025
• Figure 14-17: Generic Verapamil - Price Per Unit & Supply (US$), August'2025
• Figure 14-18: Cardizem LA - Available Dosage Strengths (mg)
• Figure 14-19: Cardizem LA - Price Per Unit & Supply Of 30 Tablets (US$), August'2025
• Figure 14-20: Cardizem LA - Price Per Unit & Supply Of 90 Tablets (US$), August'2025
• Figure 14-21: Calan SR - Available Dosage Strengths (mg)
• Figure 14-22: Calan SR - Price Per Unit & Supply Of 120 mg & 180 mg (US$), August'2025
• Figure 14-23: Calan SR - Price Per Unit & Supply Of 240 mg (US$), August'2025
• Figure 14-24: Altoprev - Available Dosage Strengths (mg)
• Figure 14-25: Altoprev - Price Per Unit & Supply (US$), August'2025
• Figure 14-26: Cardura XL - Available Dosage Strengths (mg)
• Figure 14-27: Cardura XL - Price Per Unit & Supply (US$), August'2025
• Figure 15-1: Apretude - Price Per Unit & Supply (US$), August'2025
• Figure 15-2: Cabenuva - Price Per Unit & Supply (US$), August'2025
• Figure 15-3: Rukobia - Price Per Unit & Supply (US$), August'2025
• Figure 16-1: Qelbree - Price Per Unit & Supply Of Strengths 100 mg & 150 mg (US$), August'2025
• Figure 16-2: Qelbree - Price Per Unit & Supply Of Strength 200 mg (US$), August'2025
• Figure 16-3: Global - Qelbree Annual Sales (US$ Million), 2021-2023
• Figure 16-4: Global - Qelbree Quarterly Sales (US$ Million), Q1 & Q2'2025
• Figure 16-5: Global - Qelbree Quarterly Sales (US$ Million), Q1-Q4'2024
• Figure 16-6: Jornay PM - Available Dosage Strengths (mg)
• Figure 16-7: Jornay PM - Price Per Unit & Supply (US$), August'2025
• Figure 16-8: Global - Jornay PM Annual Sales (US$ Million), 2024-2025
• Figure 16-9: Global - Jornay PM Quarterly Sales (US$ Million), Q1 & Q2'2025
• Figure 16-10: Global - Jornay PM Quarterly Sales (US$ Million), Q3-Q4'2024
• Figure 16-11: Cotempla XR-ODT - Available Dosage Strengths (mg)
• Figure 16-12: Cotempla XR-ODT - Price Per Unit & Supply (US$), August'2025
• Figure 16-13: Adzenys XR-ODT - Available Dosage Strengths (mg)
• Figure 16-14: Adzenys XR-ODT - Price Per Unit & Supply (US$), August'2025
• Figure 16-15: Global - Adzenys XR-ODT & Cotempla XR-ODT Annual Sales (US$ Million), 2021-2025
• Figure 16-16: Global - Adzenys XR-ODT & Cotempla XR-ODT Quarterly Sales (US$ Million), Q1'2025
• Figure 16-17: Global - Adzenys XR-ODT & Cotempla XR-ODT Quarterly Sales (US$ Million), Q1-Q4'2025
• Figure 16-18: Intuniv - Available Dosage Strengths (mg)
• Figure 16-19: Intuniv - Price Per Unit & Supply (US$), August'2025
• Figure 16-20: Global - Intuniv Annual Sales (US$ Million), 2020-2025
• Figure 16-21: Global - Intuniv Quarterly Sales (US$ Million), Q1 & Q2'2025
• Figure 16-22: Focalin XR - Available Dosage Strengths (mg)
• Figure 16-23: Focalin XR - Price Per Unit & Supply (US$), August'2025
• Figure 17-1: Rinvoq - Available Dosage Strengths (mg)
• Figure 17-2: Rinvoq - Price Per Unit & Supply (US$), August'2025
• Figure 17-3: Global - Rinvoq Annual Sales (US$ Million), 2020-2025
• Figure 17-4: Global - Rinvoq Quarterly Sales (US$ Million), Q1 & Q2'2025
• Figure 17-5: Global - Rinvoq Quarterly Sales (US$ Million), Q1-Q4'2024
• Figure 17-6: US - Rinvoq Annual Sales (US$ Million), 2020-2025
• Figure 17-7: US - Rinvoq Quarterly Sales (US$ Million), Q1 & Q2'2025
• Figure 17-8: US - Rinvoq Quarterly Sales (US$ Million), Q1-Q4'2024
• Figure 17-9: ROW - Rinvoq Annual Sales (US$ Million), 2020-2025
• Figure 17-10: ROW - Rinvoq Quarterly Sales (US$ Million), Q1 & Q2'2025
• Figure 17-11: ROW - Rinvoq Quarterly Sales (US$ Million), Q1-Q4'2024
• Figure 17-12: Ortikos - Available Dosage Strengths (mg)
• Figure 17-13: Ortikos - Price Per Unit & Supply (US$), August'2025
• Figure 17-14: Xeljanz XR - Available Dosage Strengths (mg)
• Figure 17-15: Xeljanz XR - Price Per Unit & Supply (US$), August'2025
• Figure 17-16: Global - Xeljanz XR Annual Sales (US$ Million), 2020-2025
• Figure 17-17: Global - Xeljanz XR Quarterly Sales (US$ Million), Q1 & Q2'2025
• Figure 17-18: Global - Xeljanz XR Quarterly Sales (US$ Million), Q1-Q4'2024
• Figure 17-19: US - Xeljanz XR Annual Sales (US$ Million), 2020-2025
• Figure 17-20: US - Xeljanz XR Quarterly Sales (US$ Million), Q1 & Q2'2025
• Figure 17-21: US - Xeljanz XR Quarterly Sales (US$ Million), Q1-Q4'2024
• Figure 17-22: ROW - Xeljanz XR Annual Sales (US$ Million), 2020-2025
• Figure 17-23: ROW - Xeljanz XR Quarterly Sales (US$ Million), Q1 & Q2'2025
• Figure 17-24: ROW - Xeljanz XR Quarterly Sales (US$ Million), Q1-Q4'2024
• Figure 17-25: Mestinon Timespan - Price Per Unit & Supply (US$), August'2025
• Figure 17-26: Generic Pyridostigmine - Price Per Unit & Supply (US$), August'2025
• Figure 17-27: Symax Duotab - Price Per Unit & Supply (US$), August'2025
• Figure 18-1: Aemcolo - Price Per Unit & Supply (US$), August'2025
• Figure 18-2: Talicia - Price Per Unit & Supply (US$), August'2025
• Figure 19-1: Sublocade - Price Per Unit & Supply (US$), August'2025
• Figure 19-2: Global - Sublocade Annual Sales (US$ Million), 2020-2025
• Figure 19-3: Global - Sublocade Quarterly Sales (US$ Million), Q1 & Q2'2025
• Figure 19-4: Global - Sublocade Quarterly Sales (US$ Million), Q1-Q4'2024
• Figure 19-5: Sublocade - Price Per Unit & Supply Of Strength 50 mg/mL (US$), August'2025
• Figure 19-6: Sublocade - Price Per Unit & Supply Of Strength 355.6 mg/mL (US$), August'2025
• Figure 20-1: Astagraf XL - Available Dosage Strengths (mg)
• Figure 20-2: Astagraf XL - Price per Unit & Supply (US$), August'2025
• Figure 20-3: Envarsus XR - Available Dosage Strengths (mg)
• Figure 20-4: Envarsus XR - Price per Unit & Supply Of 30 Tablets (US$), August'2025
• Figure 20-5: Envarsus XR - Price per Unit & Supply Of 100 Tablets (US$), August'2025
• Figure 21-1: Trokendi XR - Available Dosage Strengths (mg)
• Figure 21-2: Trokendi XR - Price per Unit & Supply (US$), August'2025
• Figure 21-3: Global - Trokendi XR Annual Sales (US$ Million), 2020-2025
• Figure 21-4: Global - Trokendi XR Quarterly Sales (US$ Million), Q1 & Q2'2025
• Figure 21-5: Global - Trokendi XR Quarterly Sales (US$ Million), Q1-Q4'2024
• Figure 21-6: Global - Oxtellar XR Annual Sales (US$ Million), 2020-2025
• Figure 21-7: Global - Oxtellar XR Quarterly Sales (US$ Million), Q1 & Q2'2025
• Figure 21-8: Global - Oxtellar XR Quarterly Sales (US$ Million), Q1-Q4'2024
• Figure 21-9: Keppra XR - Available Dosage Strengths (mg)
• Figure 21-10: Keppra XR - Price per Unit & Supply (US$), August'2025
• Figure 21-11: Generic levetiracetam - Price per Unit & Supply Of 500 mg (US$), August'2025
• Figure 21-12: Keppra XR - Price per Unit & Supply (US$), August'2025
• Figure 21-13: Global - Oxtellar XR Annual Sales (US$ Million), 2020-2025
• Figure 21-14: Roweepra XR - Available Dosage Strengths (mg)
• Figure 21-15: Roweepra XR - Price per Unit & Supply (US$), August'2025
• Figure 21-16: Depakote - Available Dosage Strengths (mg)
• Figure 21-17: Depakote - Price per Unit & Supply (US$), August'2025
• Figure 21-18: Depakote ER - Available Dosage Strengths (mg)
• Figure 21-19: Depakote ER - Price per Unit & Supply (US$), August'2025
• Figure 21-20: Depakote Sprinkles - Price per Unit & Supply (US$), August'2025
• Figure 22-1: Effexor XR - Available Dosage Strengths (mg)
• Figure 22-2: Effexor XR - Price per Unit & Supply Of 30 Capsules (US$), August'2025
• Figure 22-3: Effexor XR - Price per Unit & Supply Of 90 Capsules (US$), August'2025
• Figure 22-4: Generic Venlafaxine - Price per Unit & Supply Of 37.5 mg (US$), August'2025
• Figure 22-5: Generic Venlafaxine - Price per Unit & Supply Of 37.5 mg (US$), August'2025
• Figure 22-6: Generic Venlafaxine - Price per Unit & Supply Of 37.5 mg (US$), August'2025
• Figure 22-7: Global - Effexor XR Annual Sales (US$ Million), 201-2025
• Figure 22-8: Global - Effexor XR Quarterly Sales (US$ Million), Q1 & Q2'2025
• Figure 22-9: Global - Effexor XR Quarterly Sales (US$ Million), Q1-Q4'2024
• Figure 22-10: Xanax XR - Available Dosage Strengths (mg)
• Figure 22-11: Xanax XR - Price per Unit & Supply (US$), August'2025
• Figure 22-12: Generic Alprazolam - Price per Unit & Supply (US$), August'2025
• Figure 22-13: Ambien CR - Available Dosage Strengths (mg)
• Figure 22-14: Ambien CR - Price per Unit & Supply (US$), August'2025
• Figure 22-15: Generic Zolpidem - Price per Unit & Supply Of 6.25 mg (US$), August'2025
• Figure 22-16: Generic Zolpidem - Price per Unit & Supply Of 12.5 mg (US$), August'2025
• Figure 23-1: Klor-Con 8 - Price per Unit & Supply (US$), August'2025
• Figure 23-2: Generic Potassium Chloride - Price per Unit & Supply Of 8 mEq (US$), August'2025
• Figure 23-3: Klor-Con 10 - Price per Unit & Supply (US$), August'2025
• Figure 23-4: Klor-Con M10 - Price per Unit & Supply (US$), August'2025
• Figure 23-5: Klor-Con M15 - Price per Unit & Supply (US$), August'2025
• Figure 23-6: Generic Potassium Chloride - Price per Unit & Supply Of 15 mEq (US$), August'2025
• Figure 23-7: Klor-Con M20 - Price per Unit & Supply (US$), August'2025
• Figure 24-1: Controlled Drug Delivery System Market - Key Drivers
• Figure 24-2: Controlled Drug Delivery System Market - Major Challenges

List of Tables

• Table 1-1: Conventional vs. Novel Drug Delivery
• Table 1-2: Sustained vs. Controlled Release
• Table 5-1: Controlled Release Drugs - Recent US FDA Approvals

Global Controlled Release Drug Delivery Market, Drug Dosage, Price, Sales & Clinical Trials Insight 2030 Report Finding & Highlights:

• Research Methodology
• Global & Regional Market Overview
• Global Market Size Insight In US$ Billion: 2022 - 2030
• Global Market Opportunity: > US$ 90 Billion
• Insight On Controlled Release Drugs In Clinical Trials: > 190 Drugs
• Global Controlled Release Drugs Clinical Pipeline By Company, Indication & Phase
• Insight On Approved & Marketed Controlled Release Drugs: > 180 Drugs
• Controlled Release Drugs Dosage, Pricing & Sales Insight
• Competitive Landscape

Need for Controlled Drug Release Systems & Why This Report?

The demand for controlled drug release systems has increased as both healthcare practitioners and patients seek improved, more convenient, and safer therapeutic regimens. Chronic diseases like diabetes, cardiovascular diseases, and neurological disorders call for long-term therapy, and the limitations associated with conventional dosing, such as repeated administration and variable drug absorption, frequently undermine treatment efficacy. Controlled drug release systems resolve these issues by maintaining uniform levels of drugs for a prolonged duration, minimizing the frequency of dosing, and improving the therapeutic efficacy. Controlled drug release systems also assist in the reduction of side effects, patient compliance, and the optimization of the pharmacokinetics of drugs.

This report gives an in-depth look at the changing landscape of drug controlled release technologies, underlining the innovations, clinical trends, and key market players. With the demand for improved drug delivery increasing, this analysis is an eye opener to future growth and opportunities in this growing market. Apart from the latest technological developments and emerging trends, it also contains in-depth pricing data for more than 60 medicines, as well as sales performance data for specific products. This blend of strategic recommendations and market data is meant to guide industry participants, enabling them to make informed decisions in drug development, delivery, and commercialization.

Clinical Trials Insight Included In Report

Clinical trials are crucial in validating the efficacy and safety of drug delivery systems with controlled release. There are detailed insights into several key clinical trials in this report, and giving a preview of the development in the area. The information provided in this section specifically comprises stages of trials, sponsors, geographical distribution, technology providers, collaborators and license holders. The trials cover a variety of therapeutic categories, including pain management and oncology to neurological diseases and metabolic disorders.

Major Companies Active In R&D of Controlled Drug Release Systems

A number of major pharmaceutical and biotech firms are currently engaged in the development of controlled drug release systems. These firms are leaders in R&D activities, employing advanced technologies to develop more efficient and patient-friendly medicines. The report identifies prominent players like AbbVie, AstraZeneca, and Merck, which are looking for novel drug delivery platforms to enhance the treatment of chronic diseases as well as conditions like cancer, neurological disorders, and metabolic disorders.

Along with major pharmaceutical firms, smaller startups are also taking lead in creating new controlled release systems. Firms such as SpyGlass Pharma and Glaukos Corporation are pushing the boundaries of controlled-release platforms in ophthalmology, whereas partnerships like that of Boehringer Ingelheim with Re-Vana Therapeutics are developing biodegradable implants for retinal illnesses. The report also explains how these collaborations are spurring the commercialization of new-generation drug delivery systems.

Report Indicating Future Direction Of Controlled Drug Release Systems Segment

The future for controlled drug release systems promises significant growth and development. According to the report, the emphasis will be placed on the use of more personalized and targeted drug delivery mechanisms, sparked by developments in biotechnology and digital health technologies. The advent of precision medicine will propel the creation of customized drug release systems that respond to each patient's requirements, even further enhancing the effectiveness of treatment and patients' compliance.

Moreover, our research anticipates a wider use of non-invasive drug delivery techniques, including implantable systems and transdermal patches, as they are convenient and cause less discomfort to patients. Increasing applications in neurodegenerative disorders, personalized oncology, and rare diseases will also propel the market forward.

As investment in R&D continues and regulatory backing for innovative drug delivery technologies is further enhanced, controlled drug release system market growth will persist, presenting substantial opportunities for firms developing such sophisticated therapies.

Table of Contents

1. Introduction To Controlled Drug Delivery

• 1.1 Fundamentals & Technology
• 1.2 Classification By System, Route & Technology
• 1.3 Mechanisms Of Action

2. Material Based Approaches For Controlled Drug Delivery

• 2.1 Polymers
• 2.2 Chronopharmaceutics
• 2.3 Nanoparticulate Delivery System

3. Global Controlled Release Drug Delivery Market Trends

• 3.1 Current Market Scenario
• 3.2 Future Market Outlook

4. Controlled Drug Delivery Research & Clinical Trends By Indication

• 4.1 Neurological Disorders
• 4.2 Cardiovascular Diseases
• 4.3 Diabetes
• 4.4 Cancer
• 4.5 Microbial Infections

5. Global Controlled Release Drug Market Trends By Region

• 5.1 US
• 5.2 Europe
• 5.3 Japan
• 5.4 China
• 5.5 Canada
• 5.6 South Korea

6. Global Controlled Release Drugs Clinical Pipeline By Company, Indication & Phase

• 6.1 Research
• 6.2 Preclinical
• 6.3 Phase-I
• 6.4 Phase-I/II
• 6.5 Phase-II
• 6.6 Phase-II/III
• 6.7 Phase-III
• 6.8 Preregistration
• 6.9 Registered

7. Marketed Controlled Release Drugs Clinical Insight By Company, Country & Indication

8. Controlled Release Drugs for Alzheimer's Disease - Pricing & Dosage Insight

• 8.1 Namzaric (Extended-Release)
• 8.2 Namenda XR (Extended-Release)
• 8.3 Razadyne ER (Extended Release)

9. Controlled Release Drugs for Parkinson's Disease - Pricing & Dosage Insight

• 9.1 Gocovri (Extended-Release)
• 9.2 Osmolex ER (Extended-Release)
• 9.3 Mirapex ER (Extended-Release)

10. Controlled Release Drugs for Schizophrenia - Pricing & Dosage Insight

• 10.1 Invega (Extended-Release)
• 10.2 Invega Franchise/Invega Hafyera (Extended-Release)
• 10.3 Seroquel XR (Extended-Release)
• 10.4 Abilify Franchise (Extended-Release)
• 10.5 Aristada/Aristada Initio (Extended-Release)
• 10.6 Rykindo (Extended-Release)
• 10.7 Risperdal Consta (Extended-Release)
• 10.8 Uzedy (Extended-Release)

11. Controlled Release Drugs for Chronic & Post-Operative Pain - Pricing & Dosage Insight

• 11.1 Hysingla ER (Extended-Release)
• 11.2 Nucynta ER (Extended-Release)
• 11.3 Kadian (Extended-Release)
• 11.4 Xtampza ER (Extended-Release)
• 11.5 MS Contin (Extended-Release)
• 11.6 Embeda (Extended-Release)
• 11.7 Posimir (Sustained-Release)
• 11.8 Zynrelef (Extended-Release)
• 11.9 ConZip (Extended-Release)
• 11.10 Generic Hydromorphone (Extended-Release)

12. Controlled Release Drugs for Multiple Sclerosis - Pricing & Dosage Insight

• 12.1 Ampyra / Fampyra (Extended-Release)
• 12.2 Tecfidera (Delayed-Release)
• 12.3 Vumerity (Delayed-Release)
• 12.4 Rayos (Delayed-Release)
• 12.5 Bafiertam (Delayed-Release)

13. Controlled Release Drugs for Diabetes Mellitus Type II - Pricing & Dosage Insight

• 13.1 Glumetza (Extended-Release)
• 13.2 Glucotrol XL (Extended-Release)
• 13.3 Glucophage XR (Extended-Release)
• 13.4 Trijardy XR (Extended-Release)
• 13.5 Synjardy XR (Extended-Release)

14. Controlled Release Drugs for Cardiovascular Diseases - Pricing & Dosage Insight

• 14.1 Procardia XL (Extended-Release)
• 14.2 Toprol XL (Extended-Release)
• 14.3 Verelan PM (Extended-Release)
• 14.4 Cardizem LA (Extended-Release)
• 14.5 Calan SR (Sustained-Release)
• 14.6 Altoprev (Extended-Release)
• 14.7 Cardura XL (Extended-Release)

15. Controlled Release Drugs for HIV - Pricing & Dosage Insight

• 15.1 Apretude (Extended-Release)
• 15.2 Cabenuva (Extended-Release)
• 15.3 Rukobia (Extended-Release)

16. Controlled Release Drugs for Attention Deficit Hyperactivity Disorder - Pricing & Dosage Insight

• 16.1 Qelbree (extended-release)
• 16.2 Jornay PM (Extended-Release)
• 16.3 Cotempla XR-ODT (Extended-Release)
• 16.4 Adzenys XR-ODT (Extended-Release)
• 16.5 Intuniv (Extended-Release)
• 16.6 Focalin XR (Extended-Release)

17. Controlled Release Drugs for Inflammatory & Autoimmune Diseases - Pricing & Dosage Insight

• 17.1 Rinvoq (Extended-Release)
• 17.2 Ortikos (Extended-Release)
• 17.3 Xeljanz XR (Extended-Release)
• 17.4 Mestinon Timespan (Extended-Release)
• 17.5 Symax Duotab (Extended-Release)

18. Controlled Release Drugs for Bacterial Infections - Pricing & Dosage Insight

• 18.1 Aemcolo (Delayed-Release)
• 18.2 Talicia (Delayed-Release)

19. Controlled Release Drugs for Opioid Use Disorder - Pricing & Dosage Insight

• 19.1 Sublocade (Sustained-Release)
• 19.2 Brixadi (Extended-Release)

20. Controlled Release Drugs for Preventing Organ Transplant Rejection - Pricing & Dosage Insight

• 20.1 Astagraf XL (Extended-Release)
• 20.2 Envarsus XR (Extended-Release)

21. Controlled Release Drugs for Migraine & Seizure - Pricing & Dosage Insight

• 21.1 Trokendi XR (Extended-Release)
• 21.2 Oxtellar XR (Extended-Release)
• 21.3 Keppra XR (Extended-Release)
• 21.4 Roweepra XR (Extended-Release)
• 21.5 Depakote, Depakote ER, & Depakote Sprinkles

22. Controlled Release Drugs for Mental Health and Sleep Disorders - Pricing & Dosage Insight

• 22.1 Effexor XR (Extended-Release)
• 22.2 Xanax XR (Extended-Release)
• 22.3 Ambien CR (Extended-Release)

23. Controlled Release Drugs for Metabolic and Electrolyte Disorders - Pricing & Dosage Insight

• 23.1 Klor-Con 8, Klor-Con 10, Klor-Con M10, Klor-Con M15, Klor-Con M20

24. Global Controlled Drug Delivery System Market Dynamics

• 24.1 Market Drivers & Opportunities
• 24.2 Market Challenges & Restraints

25. Competitive Landscape

• 25.1 AbbVie
• 25.2 Antlia Bioscience
• 25.3 Arbor Pharmaceuticals (Azurity Pharmaceuticals)
• 25.4 AstraZeneca
• 25.5 Bausch Health Companies
• 25.6 Biodexa Pharmaceuticals
• 25.7 Boehringer Ingelheim
• 25.8 Camurus
• 25.9 DURECT Corporation
• 25.10 Emplicure
• 25.11 HLK Pharmacin
• 25.12 Jemincare
• 25.13 Johnson & Johnson
• 25.14 Luye Pharma Group
• 25.15 Lyndra
• 25.16 Mallinckrodt plc
• 25.17 MedinCell S.A.
• 25.18 Merck
• 25.19 Otsuka Pharmaceutical
• 25.20 Pacira BioSciences
• 25.21 Pfizer
• 25.22 Purdue Pharma
• 25.23 Roche
• 25.24 Sanofi
• 25.25 Serina Therapeutics
• 25.26 Sun Pharmaceutical Industries
• 25.27 Supernus Pharmaceuticals
• 25.28 Takeda
• 25.29 Tris Pharma
• 25.30 ViiV Healthcare